Sinclair
DERMATOLOGY

2 Wellington Parade
East Melbourne 3008
T: 1300 761 359

RECRUITING NOW

A PROSPECTIVE, RANDOMIZED, CONTROLLED, DOUBLE-BLIND STUDY THAT EVALUATES THE SAFETY AND EFFICACY OF THREE ACTIVE REVIAN CAPS VERSUS A NON-ACTIVE REVIAN CAP (SHAM) IN MALE PATTERN HAIR LOSS (MPHL)

In recent years, low-level laser/light therapy (LLLT), or photobiomodulation or photobiostimulation, has been promoted to prevent hair loss and stimulate hair growth in MPHL. REVIAN is a mobile soft dome shaped cap using LED modulated light therapy which is controlled and operated by a mobile app and is intended to be used in a home environment.

This 26 week, prospective sponsored clinical trial will investigate the safety and efficacy of REVIAN in male participants aged 18 – 60 years old who:

a) Have Androgenic Alopecia, Norwood Hamilton scales of IIa – V and Fitzpatrick skin type I – IV

b) Have never taken or stopped taking Propecia for 12 months prior to enrolment

c) Have never used or stopped using Topical or Oral Minoxidil for at 6 months prior to enrolment

d) Have not had previous hair transplant, cell treatment, micro-needling, tattooing, or any other treatment to the scalp

Patients will be randomized to 1 of 3 active treatment arms or a sham. There are 4 visits over 26 weeks. All treatments are provided free of charge. Other inclusion and exclusion criteria apply.

Patients will be reimbursed for travel costs.

If you have any patients who are suitable, please ask them to call or email Samantha Dinning to schedule a screening visit. Her number is 0455 915 411. Her email address is: clinicaltrials@sinclairdermatology.com.au